Stock Events

Amicus Therapeutics 

$10.35
38
+$0.04+0.39% Today

Statistics

Day High
-
Day Low
-
52W High
14.57
52W Low
9.02
Volume
2,967,955
Avg. Volume
2,283,212
Mkt Cap
3.07B
P/E Ratio
-20.98
Dividend Yield
-
Dividend
-

Earnings

9MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
-0.19
-0.13
-0.08
-0.02
Expected EPS
-0.07
Actual EPS
-0.02

People Also Follow

This list is based on the watchlists of people on Stock Events who follow FOLD. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap126.85B
Vertex Pharmaceuticals is a competitor because it also focuses on developing treatments for genetic diseases, similar to Amicus Therapeutics' focus on rare and orphan diseases.
Biogen
BIIB
Mkt Cap32.96B
Biogen competes in the biotechnology space, particularly in developing therapies for neurological and neurodegenerative diseases, overlapping with some of Amicus' therapeutic areas.
Alnylam Pharmaceuticals
ALNY
Mkt Cap30.08B
Alnylam Pharmaceuticals focuses on RNA interference (RNAi) therapies for genetic diseases, directly competing with Amicus' gene therapy approaches for similar conditions.
Biomarin Pharmaceutical
BMRN
Mkt Cap15.97B
BioMarin Pharmaceutical targets rare genetic diseases with its enzyme replacement therapies, closely competing with Amicus Therapeutics' product portfolio.
Sarepta Therapeutics
SRPT
Mkt Cap13.76B
Sarepta Therapeutics specializes in precision genetic medicine for rare diseases, particularly Duchenne muscular dystrophy, competing with Amicus' focus on rare genetic disorders.
Bluebird bio
BLUE
Mkt Cap114.8M
bluebird bio focuses on gene therapies for genetic diseases and cancer, competing with Amicus Therapeutics in the gene therapy space for rare diseases.
CRISPR Therapeutics
CRSP
Mkt Cap4.63B
CRISPR Therapeutics is involved in gene editing for genetic diseases, which competes with Amicus' efforts in developing therapies for rare genetic conditions.
Novartis
NVS
Mkt Cap232.42B
Novartis AG, through its advanced therapy platforms, competes in the same space as Amicus, particularly in gene therapies and treatments for rare diseases.
Pfizer
PFE
Mkt Cap169.83B
Pfizer has a growing interest in rare diseases and gene therapy, making it a competitor as it expands its portfolio in areas that overlap with Amicus Therapeutics' focus.

Analyst Ratings

17.57$Average Price Target
The highest estimate is $22.
From 8 ratings within the last 6 months. This is not an investment recommendation.
Buy
88%
Hold
13%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data. It also develops AT-GAA, a novel treatment paradigm for Pompe disease; enzyme replacement therapies for Pompe diseases; CLN3, which is in Phase 1/2 clinical study to evaluate the safety and efficacy of a single intrathecal administration of an AAV serotype AT-GTX-502 gene therapy in patients with CLN3; and CDKL5, a gene on the X-chromosome encoding the CDKL5 protein that regulates the expression of essential proteins for normal brain development. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
Show more...
CEO
John Crowley
Employees
517
Country
US
ISIN
US03152W1099
WKN
000A0MSMZ

Listings